The U.S. Supreme Court recently agreed to hear a case that pits two groups on opposite sides of the debate over prescription drug costs: community pharmacists and pharmacy benefit managers.
In the case, Rutledge v. Pharmaceutical Care Management Association, the court will consider whether the federal Employee Retirement Income Security Act (ERISA) of 1974 pre-empts an Arkansas law regulating PBMs’ drug-reimbursement rates.
One question Julie Appleby posed to a panel she moderated on the high cost of prescription drugs was simple enough: Do drug pricing reform efforts promise consumer relief?
The answer from three experts Appleby assembled for a panel discussion at Health Journalism 2019 this month in Baltimore was that, yes, efforts in Congress could provide some relief and those efforts have bipartisan support. But, as with any pending legislation, the details in the final bills will matter. Also, of course, any bill needs to pass both houses and then President Trump would need to sign it. Continue reading
Photo: Pia Christensen/AHCJMartin Van Trieste
One of the best sessions at Health Journalism 2019 in Baltimore was the panel discussion about drug prices on May 3, “Of price spikes and shortages: New initiatives to increase patient access to generic and biosimilar drugs.” Wendy Wolfson, an independent journalist from Irvine, Calif., moderated the discussion.
Perhaps the most interesting of the four panel members was Martin Van Trieste, president and CEO, Civica Rx, a nonprofit manufacturer of generic drugs for hospitalized patients. Seven of the nation’s largest health systems have invested in Civica and their representatives will serve on its board of directors along with representatives from three philanthropies: the Laura and John Arnold Foundation, the Peterson Center on Healthcare, and the Gary and Mary West Foundation. Continue reading
Drug prices have become a hot topic – and a significant source of the ongoing challenges to achieving affordable premiums and out-of-pocket costs in both Affordable Care Act exchange plans and employer-sponsored coverage. Drug costs are now the single largest health care concern of Americans across the political spectrum, according to some polls.
But it can be hard to know where to go to find out information about drug pricing and drug value (which aren’t the same thing). Continue reading